Digital Therapeutics on Inhalation Medication Adherence in COPD

Digital Therapeutics (DTx) is an evidence-based，clinically evaluated software to treat，manage，and prevent a broad spectrum of diseases and disorders according to Digital Therapeutics Alliance，which may improve the adherence of patients with chronic obstructive pulmonary disease (COPD) to use inhaled medication and reduce the risk of acute exacerbation. This study plans to carry out a randomized controlled trial (RCT), using digital therapy to record and manage the behavior data of patients with COPD in the process of using inhaler medication, and analyze the correlation between digital therapy of COPD and patients' drug compliance and treatment effect.

Inclusion Criteria:Fully understand and willing to sign the written informed consent;Local residents diagnosed COPD by physician;Aged 40 and above;Plan to receive metered-dose inhaler as long-term treatment;Have a smartphone and can apply WeChat applet after training;Exclusion Criteria:Certain comorbidities (e.g. unstable coronary complications);Undergone thoracic, abdominal or ophthalmic surgery in recent 3 months;Pregnant or lactating women;ABS allergy history.